Asston Pharmaceuticals Limited
Bookbuilding IPO · BSE
- Price band
- ₹115 - ₹123
- Lot size
- 1,000 shares
- Issue amount
- ₹27.56 cr
- Total subscription
- 186.59×
- Opens
- 9 Jul 2025
- Closes
- 11 Jul 2025
- Allotment
- 14 Jul 2025
- Listing
- 16 Jul 2025
Offer at a glance
Issue overview
- Issue size
- 22,41,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,15,000
- Fresh issue
- ₹27.56 cr
- Offer for sale
- ₹0 cr
- Registrar
- Maashitla Securities Private Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,23,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 62,71,360
- Shares after issue
- 85,12,360
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,000 | ₹2,46,000 |
| sHNI | 3 | 3,000 | ₹3,69,000 |
| bHNI | 9 | 9,000 | ₹11,07,000 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 373 | 64,208 |
| HNIs(10L +) | 72 | 8,616 |
| HNIs (2-10L) | 36 | 6,457 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 5.23 | 0 |
| RETAIL | 9.18 | 1.16 |
| HNIs 2+ | 1.33 | 0.34 |
| HNIs 10+ | 2.64 | 0 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 2.11 | 6.9 | 2.37 |
| ROE | 69.73 | 50.56 | 32.47 |
| ROCE | 79.46 | 51.25 | 34.29 |
| RONW | 40.36 | 21.28 | 53.21 |
| PRE IPO(PE) | 0 | 17.83 | 0 |
| POST IPO(PE) | 13.2 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Asston Pharmaceuticals Limited, established in 2019, is a pharmaceutical company focused on exporting healthcare products worldwide. It offers a wide range of products, including tablets, capsules, sachets, and syrups. These cover various therapeutic areas such as pain relief, antibiotics, antifungals, vitamins, and more. The company manufactures medicines for its own sales as well as on a contract basis, mainly working directly with different marketers. It holds certifications from both Central and State FDA, along with NQA accreditation, and follows Quality Management System standards to maintain product quality. As of July 3, 2025, the company employs 46 permanent staff and 6 contractual workers across different departments.
Strengths
- Strong Focus on Formulation and R&D – Specializes in developing high-quality medicines that meet international standards.
- Experienced and Skilled Management Team – Led by industry professionals with deep knowledge and a track record of business growth.
- Diverse Product Portfolio with Strategic Manufacturing – Offers a wide variety of products and operates plants near major export locations for easy distribution.
Risk factors
- Risk of Regulatory Issues – Works in a highly regulated industry; any non-compliance can affect operations and reputation.
- Dependency on Other Manufacturers – Relies on third-party makers for some products, which may impact quality and supply flow.
- Heavy Dependence on Key Clients – Large part of income depends on a few customers; losing them can affect business growth.
Promoters
Dr. Ashish Narayan Sakalkar
Saili Jayaram More
Sachin Chandrakant Badakh
Registrar & documents
Lead manager
Sobhagya Capital Options Limited
Registrar & contacts
Maashitla Securities Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
4th Floor, Office No. A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane Navi Mumbai, Maharashtra, 400614
+91 22 49731411
[email protected]Company website ↗Understanding APL IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.